The initial results suggest that Exact’s test could be an alternative to others on the market, but the findings come from a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investors with a lot of money to spend have taken a bullish stance on Exact Sciences EXAS. And retail traders should know. We noticed this today when the positions showed up on publicly available ...

Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.

but rivalries usually aren’t as contentious as what played out on social media this week when Guardant Health co-CEO AmirAli Talasaz put out a LinkedIn post betting Exact Science’s CEO $1 ...

(Exact Sciences) Meanwhile ... Cologuard box that’s become something of a mascot for the brand, coming to life on the table next to a family photo, surrounded by information about accessing ...

Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences ...

Analyst Tycho Peterson of Jefferies assigned a Buy rating on Exact Sciences (EXAS – Research Report), with a price target of $84.00. Tycho Peterson has given his Buy rating due to a combination ...

Analyst Kyle Mikson CFA of Canaccord Genuity maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price ...

Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $64.12 which represents a slight increase of $5.74 or 9.83% from the prior close of $58.38. The stock opened at $58.46 and ...